



(11)

EP 1 934 608 B8

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
G06F 7/00 ^(2006.01) **G01N 33/50** ^(2006.01)
G01N 33/564 ^(2006.01) **G01N 33/68** ^(2006.01)
G01N 33/574 ^(2006.01)

(48) Corrigendum issued on:
19.07.2017 Bulletin 2017/29

(86) International application number:
PCT/US2006/035171

(45) Date of publication and mention
of the grant of the patent:
15.03.2017 Bulletin 2017/11

(87) International publication number:
WO 2007/030771 (15.03.2007 Gazette 2007/11)

(21) Application number: **06824918.4**

(22) Date of filing: **08.09.2006**

(54) **TARGETED IDENTIFICATION OF IMMUNOGENIC PEPTIDES**

GEZIELTE IDENTIFIKATION IMMUNOGENER PEPTIDE

IDENTIFICATION CIBLÉE DE PEPTIDES IMMUNOGÈNES

(84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI
SK TR**

(30) Priority: **08.09.2005 US 714865 P**

(43) Date of publication of application:
25.06.2008 Bulletin 2008/26

(60) Divisional application:
17159896.4

(73) Proprietor: **The Henry M. Jackson Foundation for
the
Advancement of Military Medicine, Inc.
Bethesda, MD 20817 (US)**

(72) Inventors:
• **PONNIAH, Sathibalan**
Columbia, MD 21044 (US)
• **PEOPLES, George, E.**
Fulton, MD 20759 (US)
• **STORRER, Catherine, E.**
Columbia, MD 21044 (US)
• **FLORA, Michael**
Mt. Airy, MD 21771 (US)

(74) Representative: **Steinecke, Peter et al**
Müller Fottner Steinecke
Rechtsanwalts- und Patentanwaltspartnerschaft
mbB
Römerstrasse 16 b
52428 Jülich (DE)

(56) References cited:
WO-A1-94/20127 US-A- 5 726 023
US-A1- 2004 018 971 US-B2- 7 179 645

- **KNUTSON K L ET AL: "Tumor antigen-specific T helper cells in cancer immunity and immunotherapy", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 54, no. 8, 1 August 2005 (2005-08-01) , pages 721-728, XP019333158, ISSN: 1432-0851, DOI: 10.1007/S00262-004-0653-2**
- **ABRAHAM MITTELMAN ET AL: "Monoclonal and polyclonal humoral immune response to EC HER-2/NEU peptides with low similarity to the host's proteome", INTERNATIONAL JOURNAL OF CANCER, vol. 98, no. 5, 10 April 2002 (2002-04-10) , pages 741-747, XP055111438, ISSN: 0020-7136, DOI: 10.1002/ijc.10259**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 1 934 608 B8

- DAKAPPAGARI N K ET AL: "Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine", **CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US**, vol. 60, no. 14, 15 July 2000 (2000-07-15) , pages 3782-3789, XP002290184, ISSN: 0008-5472
- RAMASAMY R ET AL: "Characterisation of an inhibitory monoclonal antibody-defined epitope on a malaria vaccine candidate antigen", **IMMUNOLOGY LETTERS, ELSEVIER BV, NL**, vol. 23, no. 4, 1 February 1990 (1990-02-01), pages 305-309, XP023668953, ISSN: 0165-2478, DOI: 10.1016/0165-2478(90)90077-4 [retrieved on 1990-02-01]
- WAGNER C ET AL: "Identification of an HLA-A*02 restricted immunogenic peptide derived from the cancer testis antigen HOM-MEL-40/SSX2", **CANCER IMMUNITY, ACADEMY OF CANCER IMMUNOLOGY, CH**, vol. 3, no. 18, 1 December 2003 (2003-12-01), pages 1-15, XP002486698, ISSN: 1424-9634
- N. K. Dakappagari: "Conformational HER-2/neu B-cell epitope peptide vaccine designed to incorporate two native disulfide bonds enhances tumor cell binding and antitumor activities", **Journal of Biological Chemistry**, vol. 280, no. 1, 1 January 2004 (2004-01-01), pages 54-63, XP055047782, US ISSN: 0021-9258, DOI: 10.1074/jbc.M411020200
- ZUM BUSCHENFELDE C M ET AL: "Antihuman Epidermal Growth Factor Receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells", **CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US**, vol. 62, no. 8, 15 April 2002 (2002-04-15) , pages 2244-2247, XP002981803, ISSN: 0008-5472
- KONO K ET AL: "Trastuzumab (Herceptin) Enhances Class I-restricted antigen presentation Recognized by HER-2/neu-specific T Cytotoxic Lymphocytes", **CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US**, vol. 10, no. 7, 1 April 2004 (2004-04-01), pages 2538-2544, XP002981804, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-03-0424